Bladder Cancer Weekly

October 28, 2024

Videos

Peer-to-Peer Clinical Conversations

Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka

Sarah Psutka

Zachary Klaassen speaks with Sarah Psutka about cognitive resilience in bladder cancer care.

View

Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li

Roger Li

Roger Li discusses findings from a patient panel at the BCAN Think Tank, focusing on decision-making in BCG-unresponsive and muscle-invasive bladder cancer treatment.

View

Conference Coverage

ESMO 2024: How to Manage Patients with Durable Response on Systemic Therapy? Optimal Therapy Duration and Role De-Escalation?

ESMO 2024: SOGUG-NEOWIN: Erdafitinib Monotherapy and Erdafitinib and Cetrelimab as Neoadjuvant Treatment in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer and FGFR Gene Alterations

ESMO 2024: What Is the Role of Rechallenge with the Same Class of Agents in Advanced Disease?

ESMO 2024: Building on Standard Therapies: Novel Agents and Promising Combinations in Urothelial and Renal Cell Carcinoma

ESMO 2024: Circulating Versus Tissue-Based Biomarkers

Physician-Scientist Review Articles

Treatment Preferences and Tradeoffs Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Expert Commentary

Does the Extent of Transurethral Resection after Radiation Therapy Impact Survival Outcomes in Muscle-Invasive Bladder Cancer - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Trends in the use of immediate postoperative intravesical chemotherapy following transurethral resection of bladder tumors.

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.

Artificial intelligence-based assessment of pre-operative body composition is associated with early complications after radical cystectomy.

VI-RADS-Based Algorithm for Bladder Cancer Management Randomized Retrospective Study.

Comparing direct medical care costs of patients with bladder cancer who received an ileal conduit vs. neobladder in the year following cystectomy.

Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs.

En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis of Oncological, Histopathological, and Surgical Outcomes.

Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma.

Exposures and Bladder Cancer Risk Among Military Veterans: A Systematic Review and Meta-analysis - Beyond the Abstract

Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login